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Surgical Stress Promotes Tumor Growth in Ovarian Carcinoma
Jeong-WonLee,1,4MianM.K.Shahzad,1,3YvonneG.Lin,1GuillermoArmaiz-Pena,1LingegowdaS.Mangala,1
Hee-DongHan,1Hye-SunKim,1,5 EunJiNam,1,6NicholasB. Jennings,1JyotsnabaranHalder,1
AlpaM.Nick,1Rebecca L. Stone,1Chunhua Lu,1Susan K. Lutgendorf,7 Steve W.Cole,8
Anna E. Lokshin,9 andAnil K. Sood1,2
Abstract Purpose: Surgical stress has been suggested to facilitate the growth of preexisting micrometa-
stases as well as small residual tumor postoperatively.The purpose of this study was to examine
the effects of surgical stress on ovarian cancer growth and to determine underlying mechanisms
responsible for increased growth.
Experimental Design: To mimic the effects of surgery, we did a laparotomy or mastectomy
under isoflurane inhalation on athymic nude mice 4 days after i.p. tumor cell injection. Propranolol
infusion via Alzet pumps was used to block the influence of sympathetic nervous system
activation by surgical stress.
Results: In both HeyA8 and SKOV3ip1 models, the mice in the laparotomy and mastecto-
my groups had significantly greater tumor weight (P < 0.05) and nodules (P < 0.05) com-
pared with anesthesia only controls. There was no increase in tumor weight following
surgery in the h-adrenergic receptor ^ negative RMG-II model. Propranolol completely
blocked the effects of surgical stress on tumor growth, indicating a critical role for h-
adrenergic receptor signaling in mediating the effects of surgical stress on tumor growth.
In the HeyA8 and SKOV3ip1 models, surgery significantly increased microvessel den-
sity (CD31) and vascular endothelial growth factor expression, which were blocked by
propranolol treatment.
Conclusion: These results indicate that surgical stress could enhance tumor growth and
angiogenesis, and h-blockade might be effective in preventing such effects.
Surgical cytoreduction is a critical component of cancer
therapy for many tumor types, including ovarian cancer. In
clinical practice, outgrowth of distant metastasis has been
described following surgical removal of primary tumors (1).
This observation has been further supported by several models
that have shown increased tumor growth and metastatic spread
following surgery (2–7). There are several potential mecha-
nisms for the effects on tumor growth by surgical stress,
including shedding of tumor cells due to physical manipulation
(8, 9), a drop in the level of antiangiogenic factors (10), local
and systemic release of growth factors or cytokines (11), and
suppression of cell-mediated immunity (12). However, the
mechanisms by which surgical stress promotes tumor growth
are not fully understood.
To date, no reliable screening methods to detect ovarian
cancer at an early stage have been developed. Thus, f70% of
women with newly discovered ovarian cancer have advanced
disease at the time of diagnosis (13). Nevertheless, a complete
clinical remission can be achieved in f80% of these patients
with the use of maximal surgical cytoreduction and platinum-
based combination chemotherapy (14). Unfortunately, up-
wards of 75% of those with complete clinical response will
develop recurrent disease. Reoperation with secondary tumor
resection has become an option for many ovarian cancer
patients. Therefore, women with ovarian cancer frequently
undergo several surgical procedures throughout the course of
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their disease. Given the paucity of information about the effects
of surgery on ovarian cancer growth, we examined the effects of
laparotomy and extraperitoneal surgery on ovarian cancer
growth and angiogenesis using orthotopic animal models.
Materials andMethods
Ovarian cell lines and culture conditions. The ovarian cancer cell
lines HeyA8, SKOV3ip1, and RMG-II were cultured in RPMI 1640
supplemented with 10% (RMG-II) to 15% (HeyA8 and SKOV3ip1) fetal
bovine serum and 0.1% gentamicin sulfate (Gemini Bioproducts; refs.
15–17). For in vivo injections, cells were trypsinized and centrifuged at
1,000 rpm for 7 min at 4jC, washed twice with PBS, and reconstituted
in serum-free HBSS (Life Technologies/Invitrogen). Only single-cell
suspensions with >95% viability, as determined by trypan blue
exclusion, were used for in vivo injections. All experiments were done
using cells grown to 60% to 80% confluence, and all cell lines were
routinely tested to confirm absence of Mycoplasma .
Animal care and orthotopic implantation of tumor cells. Female
athymic mice (NCr-nu) were purchased from the National Cancer
Institute-Frederick Cancer Research and Development Center. The mice
were housed and maintained under specific pathogen-free conditions
in facilities approved by the American Association for Accreditation of
Laboratory Animal Care and in accordance with the current regulations
and standards of the U.S. Department of Agriculture, the U.S.
Department of Health and Human Services, and the NIH. All studies
were approved and supervised by the University of Texas M. D.
Anderson Cancer Center Institutional Animal Care and Use Committee.
To produce tumors, HeyA8 (2.5  105 cells/0.2 mL HBSS), SKOV3ip1
(1.0  106 cells/0.2 mL HBSS), or RMG-II (5.0  106 cells/0.2 mL
HBSS) were injected i.p. into the peritoneal cavity of mice (15–17).
The number of cells injected for each cell line was established
previously based on the lowest number of cells required to reliably
produce tumors. The mice used in these experiments were 8 to 12 wk
old. Mice (n = 10 per group) were monitored daily for tumor
development and postoperative complications and were sacrificed on
days 25 to 30 (HeyA8), days 35 to 40 (SKOV3ip1), or days 40 to 50
(RMG-II) or when any of the mice seemed moribund. Total body
weight, tumor incidence and mass, and the number of tumor nodules
were recorded. Tumors were fixed in formalin and embedded in
paraffin or snap frozen in OCT compound (Sakura Finetek USA, Inc.)
in liquid nitrogen.
Generation of orthotopic in vivo model of surgical stress. For surgery,
animals were exposed to an experimental mastectomy or laparotomy
under isoflurane inhalation (Baxter) anesthesia. The surgical procedure
for mastectomy consisted of a midline chest wall skin incision and
removal of right mammary tissues from the chest wall. The skin of chest
wall was closed with three to four surgical clips. The laparotomy
consisted of a 4-cm midline abdominal incision followed by the
externalization of intestines for a period of 4 min as described
previously by Ben-Eliyahu and colleagues (18, 19). During the
laparotomy, the small intestine was rubbed with two saline-soaked
cotton Q-tips in four locations to simulate a surgical procedure. The
intestine was then returned to the abdominal cavity and irrigated with
saline, and the abdominal wall was closed with surgical clips (20, 21).
To examine the influence of h-adrenergic signaling for surgical stress,
we used the nonspecific h-adrenergic receptor (ADRB) antagonist (S)-
propranolol hydrochloride (2 mg/kg/d; Sigma) given via Alzet mini-
osmotic pumps (model 2004, DURECT Corp.; refs. 22, 23). We inserted
the minipumps containing PBS or propranolol on the nape of neck 7 d
before surgical stress (24).
Immunohistochemistry for CD31, vascular endothelial growth factor,
and proliferating cell nuclear antigen. To quantify angiogenesis,
microvessel density (MVD) was ascertained by counting CD31-positive
vessels as described previously (15). In brief, 8-Am sections of fresh-
frozen samples were fixed and incubated with anti-mouse CD31
(1:800; Pharmingen) at 4jC overnight. Immunohistochemical proce-
dures for vascular endothelial growth factor (VEGF) and proliferating
cell nuclear antigen (PCNA) were done as described previously (25). In
brief, for detecting VEGF and PCNA immunoreactivity, formalin-fixed,
paraffin-embedded serial sections were deparaffinized by sequential
washes with xylene followed by descending grades of ethanol.
Depending on the antibody used, antigen retrieval was achieved by
either citrate buffer (pH 6.0) in a steamer (PCNA) or pepsin in a 37jC
humidified incubator (VEGF). Endogenous peroxidases were blocked
with 3% H2O2 in methanol. Nonspecific proteins and exposed epitopes
were blocked with 5% normal horse serum/1% normal goat serum, and
slides were incubated at 4jC overnight with the respective primary
antibody at the following dilutions: 1:100 VEGF (Santa Cruz
Biotechnology) or 1:50 PCNA (Dako). After PBS washing, the
appropriate secondary antibody was applied for 1 h at room
temperature. Visualization was achieved with 3,3¶-diaminobenzidine
chromogen. All counterstaining was done with Gill’s hematoxylin
(Sigma-Aldrich).
Microscopic quantitative analyses of MVD and PCNA. To quantify
MVD, 10 random fields at 100 magnification per slide were examined
for each tumor (1 slide per mouse, 5 slides per treatment group) and
the number of microvessels per field was counted by two investigators
(J-W.L. and H-S.K.) in a blinded fashion. A single microvessel was
defined as a discrete cluster or single cell stained positive for CD31 with
the presence of a lumen (17). To quantify PCNA expression, the
number of PCNA-positive cells and the total number of tumor cells
were counted in five random fields at 100 magnification followed by
calculation of the percentage of positive cells (17).
Measurement of cytokines/chemokines in serum of mice after surgical
stress. To check the cytokines and chemokines in serum of mice, we
used multiplexing xMAP technology to analyze mouse Cytokine/
Chemokine 17 Plex Panel (Bio-Rad Laboratories) that included
granulocyte colony-stimulating factor (G-CSF), granulocyte macro-
phage colony-stimulating factor (GM-CSF), IFN-g, interleukin (IL)-1a,
IL-1h, IL-6, IL-10, IL-12 (p70), IL-15, MCP-1, M-CSF, MIG, macrophage
inflammatory protein (MIP)-1a, MIP-1h, MIP-2, RANTES, and tumor
necrosis factor a (TNFa). Blood samples were taken from hearts during
inhalation anesthesia to minimize further stress. Serum samples were
also obtained from tumor-bearing mice 6 h, 1 d, 3 d, and 5 d later after
laparotomy (n = 2 per group). Appropriate control samples were
obtained from mice exposed to isoflurane inhalation alone. Multiplex
xMAP assays were done according to the manufacturer’s protocols.
Samples were analyzed using the Bio-Plex suspension array system
Translational Relevance
Surgical cytoreduction is considered a critical compo-
nent of cancer therapy for many tumor types, including
ovarian cancer. Some surgeons have observed rapid tumor
regrowth shortly after primary surgery. Moreover, women
with ovarian cancer frequently undergo several surgical
procedures throughout the course of their disease.Surgical
stress has been suggested to facilitate the growth of pre-
existing micrometastases as well as small residual tumor
postoperatively. The key findings from our study are that
increased angiogenic processes mediated by surgical
stress could promote ovarian cancer growth in vivo. This
increase in tumor growth could be completely blocked by
a h-adrenergic receptor antagonist (propranolol). These
findings could have significant implications for the perio-
perativemanagement of cancer patients to prevent surgical
stress ^ induced tumor growth and angiogenesis.
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(Bio-Rad Laboratories). For each analyte, 100 beads were analyzed and
means were calculated. Analysis of experimental data was done using
four-parametric curve fitting to the standard analyte curves.
Statistical methods. Continuous variables were compared with the
Student’s t test or ANOVA if normally distributed and the Mann-
Whitney rank sum test if distributions were nonparametric using
Statistical Package for the Social Sciences (SPSS, Inc.). A P value of
<0.05 was considered statistically significant.
Results
Effect of surgical stress on tumor growth. To mimic the effects
of surgery, we did a laparotomy on mice 4 days after tumor cell
injection. In addition, to account for possibility of local effects,
we also did a mastectomy on a separate group of animals. In the
ADRB-positive HeyA8 and SKOV3ip1 models, laparotomy
resulted in 370% (HeyA8) and 263% (SKOV3ip1) increases in
tumor weight (P < 0.05 for both models; Fig. 1). Mastectomy
also increased tumor weight by 203% (HeyA8) and 226%
(SKOV3ip1; P < 0.05) compared with anesthesia only controls
(Fig. 1). Similarly, the number of tumor nodules was also
significantly greater following a laparotomy in both models
(P < 0.05; data not shown). Because the sympathetic nervous
system is activated during surgery (19, 26), we next asked
whether tumor cells with ADRB expressionmight be responsible
for the increased tumor growth. To address this question, we
first used an ADRB-null model using the RMG-II cells that were
negative for both ADRB1 and ADRB2, as previously shown by
reverse transcription-PCR, Western blot, and lack of intracellular
cyclic AMP response to norepinephrine or isoproterenol (24). In
this model, there was no difference in tumor weight between the
control and laparotomy groups (0.32 versus 0.28 g; P = 0.42;
Fig. 1). There were no significant differences in the body weight
of animals between the groups, suggesting that surgery did not
adversely affect the overall well-being of the animals. Next, we
examined whether a h-blocker would abrogate the increased
tumor growth. For these experiments, we used the SKOV3ip1
model and inserted a mini-osmotic pump containing propran-
olol into the mice to deliver the drug continuously. There were
no significant complications associated with pump insertion
into the mice. Figure 2 shows that either mastectomy or
laparotomy resulted in significantly increased tumor weight
compared with controls in the group with PBS-containing
pumps. Treatment with propranolol had no significant effect on
tumor growth in the anesthesia only controls. However,
treatment with continuous propranolol infusion was able to
block the increased tumor growth observed in response to either
mastectomy or laparotomy (Fig. 2).
Effect of surgical stress on angiogenesis and cell prolifera-
tion. Based on our prior findings related to the effects of stress
hormones on tumor growth and angiogenesis (24), we
Fig. 1. Effect of surgical stress on in vivo ovarian
cancer growth. Quantification of tumor weights in
control (anesthesia alone) mice and in surgically
stressed mice (mastectomy or laparotomy) that were
injected i.p. with HeyA8, SKOV3ip1, or RMG-II ovarian
cancer cells. Results represent the meanF SE; n = 10
mice per group. *, P < 0.05, compared with control
group.
Surgical Stress PromotesTumor Growth in Ovarian Cancer
www.aacrjournals.org Clin Cancer Res 2009;15(8) April 15, 20092697
Cancer Research. 
on January 27, 2014. © 2009 American Association forclincancerres.aacrjournals.org Downloaded from 
considered whether tumor angiogenesis might be stimulated
following surgery. When we examined MVD in the harvested
tumors, surgical stress resulted in significantly greater MVD
counts (P < 0.05) in the HeyA8 (Fig. 3A) and SKOV3ip1
(Supplementary Fig. S1) models. But these findings were not
present in the ADRB-null RMG-II model (Fig. 3B). Moreover,
surgical stress showed increased VEGF staining compared with
controls in the HeyA8 (Fig. 3A) and SKOV3ip1 (Supplementary
Fig. S1) models. There was no difference in VEGF expression in
the RMG-II model (Fig. 3B). We also examined the effects of
surgery on tumor cell proliferation using PCNA staining. In the
HeyA8 (Fig. 3A) and SKOV3ip1 (Supplementary Fig. S1)
models, positive staining of PCNA expression was significantly
increased in the tumor following a mastectomy or laparotomy
compared with controls (P < 0.05, both). But in the RMG-II
model, there was no significant difference between the two
groups (Fig. 3B).
To determine the effect of propranolol on angiogenesis in
surgical stress, we did immunohistochemistry for angiogenesis
markers in tumor samples. Increased MVD and VEGF by
surgery were blocked by propranolol (Fig. 4).
Level of cytokine/chemokine in mouse serum after surgical
stress. It is likely that other cytokines may be activated
during the physiologic response to surgery. Therefore, we
examined a panel of 17 cytokines and chemokines, including
G-CSF, GM-CSF, IFN-g, IL-1a, IL-1h, IL-6, IL-10, IL-12 (p70),
IL-15, MCP-1, M-CSF, MIG, MIP-1a, MIP-1h, MIP-2,
RANTES, and TNFa, in mouse serum after surgical stress.
Serum samples were obtained from tumor-bearing mice with
control (anesthesia with isoflurane inhalation alone) 6 hours,
1 day, 3 days, and 5 days later after laparotomy (n = 2 of
each group). Concentrations of G-CSF, IL-1a, IL-6, and IL-15
were significantly higher during the perioperative period
(Fig. 5).
Fig. 2. Effect of propranolol (h-antagonist) in the SKOV3ip1model for surgical stress.Tumor weight (A) and the number of nodules (B) following treatment with the
propranolol (2mg/kg/d) usingosmoticminipumps. Results represent themeanF SE; n =10miceper group. *,P < 0.05, comparedwith control group;#,P < 0.05, compared
with each stress + PBSgroup.
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Discussion
The key findings from our study are that increased
angiogenic processes mediated by surgical stress could promote
ovarian cancer growth in vivo . The greater tumor growth was
associated with increased angiogenesis and could be complete-
ly blocked by ADRB blockade. Based on these findings,
perioperative use of a h-blocker could have preventive effects
for surgical stress–induced tumor growth in ovarian cancer
patients.
Surgery, as a stressor, could increase the risk of postoperative
metastases and their underlying signaling mechanisms via local
or systemic effects. Some reports have suggested that a surgical
wound has important roles in mediating the effects of surgical
stress as a source of tumor-stimulating factors (11, 27, 28).
These reports suggested that growth factors or cytokines
Fig. 3. Proliferation and angiogenesis in tumor tissues is increased in tumors harvested from animals exposed to surgical stress. A, HeyA8 tumor samples from control
(anesthesia alone) or surgically (mastectomy or laparotomy) stressed animals were stained for CD31,VEGF, and PCNA by immunohistochemistry. B, RMG-II (ADRB null)
tumor samples frommice exposed to surgery did not show any differences in CD31,VEGF, and PCNA staining between control and laparotomy. All photographs were taken at
original magnification 100.The bars in the graphs correspond sequentially to the labeled columns of images at left. Bars, SE. *, P < 0.05.
Surgical Stress PromotesTumor Growth in Ovarian Cancer
www.aacrjournals.org Clin Cancer Res 2009;15(8) April 15, 20092699
Cancer Research. 
on January 27, 2014. © 2009 American Association forclincancerres.aacrjournals.org Downloaded from 
released by wounding could contribute to creating a suitable
environment for tumor growth (11). Wound healing and
tumor progression both involve processes of cell proliferation,
inflammation, and angiogenesis. In contrast to local effects,
Ben-Eliyahu et al. suggested that surgical stress results in
systemic activation of the hypothalamic-pituitary-adrenal axis
and the sympathetic nervous system, resulting in suppressed
natural killer cell response to tumor cells (29, 30). They also
found that combined use of a h-blocker and a prostaglandin
synthesis inhibitor restored natural killer function (19).
We recently reported that chronic (immobilization) stress
promotes tumor development and progression via h-adrenergic
activation of the cyclic AMP–protein kinase A signaling
pathways in an orthotopic murine model of ovarian carcinoma
(24). In addition to stress, understanding the mechanisms
responsible for mediating the effects of surgical stress on
human tumor tissues is crucial for determining the full effect of
this stressor on tumorigenesis and for devising effective
interventions. Our results indicate that surgical stress promotes
tumor growth by activating ADRB on tumor cells. Biologically,
Fig. 4. The effect of propranolol on angiogenesis
in surgically stressed mice. SKOV3ip1tumor samples
obtained from control or surgically stressed mice
were treated with placebo (PBS) or propranolol
pump and stained for CD31 (A) andVEGF (B) by
immunohistochemistry. All photographs were taken at
original magnification 100. Bars, SE. *, P < 0.05.
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the acceleration in tumor growth is associated with increased
angiogenesis and increased VEGF production. This premise is
supported by our finding that even surgery at an extraperitoneal
site (i.e., mastectomy) promoted i.p. tumor growth (Fig. 1).
Our findings related to the efficacy of a h-blocker in abrogating
surgically induced tumor growth suggest that such an approach
may hold utility for cancer patients undergoing surgery (Fig. 2).
Our findings about activation of angiogenesis by surgical
stress are consistent with work from our and other groups
showing the effects of stress on angiogenic factors (Figs. 3
and 4; refs. 24, 31).
Although we focused on sympathetic influence and angio-
genesis in the current study, it is possible that other
mechanisms might be operative as well in mediating the effects
of stress. Therefore, we analyzed several cytokines and chemo-
kines in serum following surgery (Fig. 5). Indeed, several
cytokines were elevated, which might also be involved in the
effects of surgical stress on tumor growth (32–34).
Results from the present study further expand our under-
standing of mechanisms by which surgical stress promotes
tumor growth. Previous studies have shown decrements in
immune function (e.g., suppressed natural killer cell response)
following surgery that creates a permissive environment for
tumor growth (29, 30). Our results using a partially immuno-
deficient model suggest direct pathways by which surgical stress
can modulate the tumor microenvironment. It is possible that
immune compromise along with direct effects of surgical stress
on tumor cells may result in even greater promotion of tumor
growth in immune competent models.
In summary, increased angiogenic processes induced by
surgical stress promote tumor growth in vivo . These effects can
be effectively blocked by a h-blocker such as propranolol. These
findings could have significant implications for the perioper-
ative management of cancer patients.
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